Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA Jr, Hirsch FR.

J Clin Oncol. 2012 Jun 20;30(18):2248-55. doi: 10.1200/JCO.2011.38.9411. Epub 2012 Apr 16.


Supportive care.

Witta SE.

J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S472-3. doi: 10.1097/01.JTO.0000391371.86753.d9. No abstract available.


Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA Jr, Varella-Garcia M, Hirsch FR.

J Clin Oncol. 2010 May 1;28(13):2174-80. doi: 10.1200/JCO.2009.24.6611. Epub 2010 Mar 29.


ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA Jr, Hirsch FR.

Ann Oncol. 2009 Apr;20(4):689-95. doi: 10.1093/annonc/mdn703. Epub 2009 Jan 15.


Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr.

Mol Cancer Res. 2006 Aug;4(8):521-8.


Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Bunn PA Jr, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR.

Clin Cancer Res. 2006 Jun 15;12(12):3652-6. Review. No abstract available.


Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.

Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA Jr, Varella-Garcia M, Danenberg KD, Hirsch FR.

Clin Cancer Res. 2006 May 15;12(10):3078-84.


Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA Jr.

Cancer Res. 2006 Jan 15;66(2):944-50.


Characterization of the Bex gene family in humans, mice, and rats.

Alvarez E, Zhou W, Witta SE, Freed CR.

Gene. 2005 Aug 29;357(1):18-28.


A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.

Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG.

Clin Cancer Res. 2004 Nov 1;10(21):7229-37.


Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats.

Zawada WM, Cibelli JB, Choi PK, Clarkson ED, Golueke PJ, Witta SE, Bell KP, Kane J, Ponce de Leon FA, Jerry DJ, Robl JM, Freed CR, Stice SL.

Nat Med. 1998 May;4(5):569-74.


Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells.

Clarkson ED, Rosa FG, Edwards-Prasad J, Weiland DA, Witta SE, Freed CR, Prasad KN.

Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1265-70.


XIPOU 2 is a potential regulator of Spemann's Organizer.

Witta SE, Sato SM.

Development. 1997 Mar;124(6):1179-89.


XIPOU 2, a noggin-inducible gene, has direct neuralizing activity.

Witta SE, Agarwal VR, Sato SM.

Development. 1995 Mar;121(3):721-30.

Supplemental Content

Loading ...
Support Center